Stonebridge Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.1M Buy
26,102
+697
+3% +$335K 0.84% 41
2026
Q1
$12.5M Sell
25,405
-114
-0.4% -$61.9K 0.87% 41
2025
Q4
$14.8M Sell
25,519
-140
-0.5% -$79.2K 1.02% 34
2025
Q3
$12.4M Buy
25,659
+130
+0.5% +$60.5K 0.89% 39
2025
Q2
$10.4M Buy
25,529
+82
+0.3% +$34.3K 0.79% 44
2025
Q1
$12.7M Buy
25,447
+786
+3% +$426K 1.03% 36
2024
Q4
$12.8M Buy
24,661
+499
+2% +$274K 1.03% 34
2024
Q3
$14.9M Sell
24,162
-695
-3% -$411K 1.22% 26
2024
Q2
$13.7M Sell
24,857
-7
-0% -$4.01K 1.21% 27
2024
Q1
$14.5M Buy
24,864
+198
+0.8% +$111K 1.3% 26
2023
Q4
$13.1M Buy
24,666
+710
+3% +$344K 1.31% 23
2023
Q3
$12.1M Buy
23,956
+533
+2% +$284K 1.33% 22
2023
Q2
$12.2M Buy
23,423
+170
+0.7% +$91.7K 1.3% 23
2023
Q1
$13.4M Buy
23,253
+381
+2% +$215K 1.53% 14
2022
Q4
$12.6M Buy
22,872
+566
+3% +$300K 1.49% 18
2022
Q3
$11.3M Buy
22,306
+461
+2% +$258K 1.46% 17
2022
Q2
$11.9M Buy
21,845
+496
+2% +$273K 1.44% 16
2022
Q1
$12.6M Buy
21,349
+815
+4% +$468K 1.36% 20
2021
Q4
$13.7M Buy
20,534
+428
+2% +$267K 1.51% 15
2021
Q3
$11.5M Sell
20,106
-305
-1% -$167K 1.4% 17
2021
Q2
$10.3M Buy
20,411
+1,319
+7% +$622K 1.25% 26
2021
Q1
$8.71M Buy
19,092
+1,877
+11% +$896K 1.15% 32
2020
Q4
$8.02M Buy
17,215
+62
+0.4% +$29.1K 1.21% 28
2020
Q3
$7.57M Sell
17,153
-336
-2% -$139K 1.36% 25
2020
Q2
$6.34M Sell
17,489
-794
-4% -$266K 1.17% 34
2020
Q1
$5.18M Sell
18,283
-470
-3% -$148K 1.09% 34
2019
Q4
$6.09M Sell
18,753
-78
-0.4% -$23.7K 0.99% 40
2019
Q3
$5.49M Sell
18,831
-11,785
-38% -$3.37M 0.95% 46
2019
Q2
$8.99M Sell
30,616
-2,650
-8% -$730K 1.6% 12
2019
Q1
$9.11M Sell
33,266
-143
-0.4% -$35.6K 1.69% 9
2018
Q4
$7.48M Sell
33,409
-1,616
-5% -$379K 1.74% 14
2018
Q3
$8.55M Sell
35,025
-735
-2% -$169K 1.72% 12
2018
Q2
$7.41M Buy
35,760
+339
+1% +$72K 1.61% 17
2018
Q1
$7.31M Sell
35,421
-1,135
-3% -$238K 1.68% 13
2017
Q4
$6.94M Sell
36,556
-595
-2% -$114K 1.59% 17
2017
Q3
$7.03M Sell
37,151
-472
-1% -$85.5K 1.73% 12
2017
Q2
$6.56M Sell
37,623
-346
-0.9% -$58.1K 1.72% 15
2017
Q1
$5.83M Buy
37,969
+1,338
+4% +$205K 1.59% 17
2016
Q4
$5.17M Sell
36,631
-1,115
-3% -$164K 1.53% 16
2016
Q3
$6M Buy
37,746
+920
+2% +$142K 1.88% 9
2016
Q2
$5.44M Sell
36,826
-4,837
-12% -$714K 1.85% 14
2016
Q1
$5.9M Sell
41,663
-1,021
-2% -$137K 2.08% 10
2015
Q4
$6.05M Buy
42,684
+1,091
+3% +$146K 2.21% 9
2015
Q3
$5.09M Buy
41,593
+1,505
+4% +$196K 2.05% 10
2015
Q2
$5.2M Buy
40,088
+1,390
+4% +$181K 2% 9
2015
Q1
$5.2M Buy
38,698
+1,826
+5% +$235K 2.01% 7
2014
Q4
$4.62M Buy
36,872
+2,470
+7% +$300K 1.9% 9
2014
Q3
$4.19M Buy
34,402
+1,245
+4% +$151K 1.85% 9
2014
Q2
$3.91M Buy
33,157
+745
+2% +$87.7K 1.76% 11
2014
Q1
$3.9M Buy
32,412
+186
+0.6% +$22.1K 1.91% 8
2013
Q4
$3.59M Buy
+32,226
New +$3.2M 1.85% 10

Other funds holding TMO

Stonebridge Capital Advisors's TMO Position: Q2 2026 in Review

Stonebridge Capital Advisors increased its Thermo Fisher Scientific (TMO) stake by 2.7% in Q2 2026, buying an estimated $335K and bringing the position to 26,102 shares worth $13.1M. The position accounts for 0.84% of the portfolio, ranked #41.

Stonebridge Capital Advisors first reported a position in TMO in Q4 2013 and has held it in 51 quarters since. The position peaked at $14.9M in Q3 2024. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Stonebridge Capital Advisors held 26,102 shares of Thermo Fisher Scientific worth $13.1M as of Q2 2026.
  • Stonebridge Capital Advisors bought 697 Thermo Fisher Scientific shares in Q2 2026, an estimated $335K.
  • Thermo Fisher Scientific made up 0.84% of Stonebridge Capital Advisors's portfolio in Q2 2026, its #41 holding.
  • Stonebridge Capital Advisors first reported a position in Thermo Fisher Scientific in Q4 2013 and has held it in 51 quarters since.
  • Stonebridge Capital Advisors's Thermo Fisher Scientific position peaked at $14.9M in Q3 2024.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.